

BIOGEN IDEC INC.

ISIN: US09062X1037 WKN: 09062X103 Asset Class: **Stock**

Company 2023/03/21 21:00:01

 **Price**
266.15
USD

Difference  **-0.66%(-1.76)**



Contact Details

BIOGEN INC. Tel: +1-617-679-2000
-- Fax: +
225 Binney Street Web: <http://www.biogen.com>
02142 Cambridge E-mail: info@biogen.com

Company Profile

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Financial figures

Financial figures	2022		2021		2020	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	9,791,200,000		7,856,500,000		6,887,100,000	
Common stock capital		100,000		100,000		100,000
Fixed assets	14,762,900,000		16,020,800,000		17,731,800,000	
Equity capital of a company		13,388,400,000		10,959,700,000		10,686,100,000
Cash and cash equivalents	3,419,300,000		2,261,400,000		1,331,200,000	
Accrued liabilities		0		0		0
Other assets	-		-		-	
Current liabilities		3,272,800,000		4,298,200,000		3,742,200,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		7,892,900,000		8,619,400,000		10,190,600,000
Different income		-		-		-
Other liabilities		944,200,000		1,320,500,000		1,329,600,000
Total assets	24,554,100,000	24,554,100,000	23,877,300,000	23,877,300,000	24,618,900,000	24,618,900,000

Balance notes

	2022	2021	2020
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	8,725	9,610	9,100
Equity ratio	54.49%	46.17%	43.35%
Debt-equity ratio	83.53%	116.61%	130.69%

Others

	2022	2021	2020
Tax Expense Rate	17.62%	3.01%	19.66%

BIOGEN IDEC INC.

ISIN: US09062X1037 WKN: 09062X103 Asset Class: **Stock**

Income statement

	2022	2021	2020
Turnover	9,433,400,000	10,402,400,000	12,356,000,000
Net income	3,046,900,000	1,556,100,000	4,000,600,000
EBIT	3,526,669,680	1,895,367,240	4,959,642,600
Operating income before taxes	3,591,800,000	1,745,200,000	5,047,500,000
Cash Flow	1,384,300,000	3,639,900,000	4,229,800,000
Net interest income	-174,400,000	-278,900,000	-249,000,000
Research and development expenses	1,958,700,000	2,265,900,000	3,789,000,000
Income taxes	632,800,000	52,500,000	992,300,000
Result from investments in subsidiaries, associates and other	2,600,000	34,900,000	5,300,000
Revenues per employee	1,012,428	1,013,612	1,271,446

Board of Directors

Members of Management Board

Stelios Papadopoulos	Chairman of Board of Directors
Alexander Denner	Member of Board of Directors
Eric Rowinsky	Member of Board of Directors
Maria Freire	Member of Board of Directors
Richard Mulligan	Member of Board of Directors
Stephen Sherwin	Member of Board of Directors
Caroline Dorsa	Member of Board of Directors
Jesus Mantas	Member of Board of Directors
William Hawkins	Member of Board of Directors
William Jones	Member of Board of Directors
Christopher Viehbacher	Chairman of Managing Board
Anabella Villalobos	Member of Executive Committee
Ginger Gregory	Member of Executive Committee
Jake Elkins	Member of Executive Committee
Mahalakshmi Radhakrishnan	Member of Executive Committee
Priya Singhal	Member of Executive Committee
Rohin Mhatre	Member of Executive Committee
Michael Dambach	Member of Executive Committee
Michael Hencke	Member of Executive Committee
Michael McDonnell	Member of Executive Committee
Nicole Murphy	Member of Executive Committee
Rachid Izzar	Member of Executive Committee
Robert Kilo	Member of Executive Committee
Robin Kramer	Member of Executive Committee
Susan Alexander	Member of Executive Committee